A cell and gene therapy platform company developing a scalable AAV production system, requested Alacrita’s guidance on the priority order for AAV vector capsid serotype release and the identity of therapeutics to target for each release. Alacrita was tasked with researching gene therapies in development, including various companies, serotypes used, and stage of development, among others, to help better understand future trends and the direction of movement within the industry.
An Alacrita consultant with expertise in gene therapies and AAV vectors, working closely with other Alacrita consultants, first assembled a global market landscape of AAV gene therapy products in development, by company. We provided the client with a database detailing companies, transgenes, clinical indication(s), stage of development, and capsid serotypes utilized. We categorized the most commonly employed capsid serotypes by phase of development and therapeutic indication, enabling a prioritization by the client on the timing of their vector releases.
Our Opportunity Mapping Expertise
We can gauge and rank the opportunities for your R&D programs or technology platforms to deliver value, by framing the commercial potential and charting the path to market.Back